Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants

  • Soligenix Inc (NASDAQ:SNGX) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs).
  •  The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. 
  • The NHPs had been double vaccinated with an adenovirus vaccine for COVID-19 seven months previously. 
  • Before administering the booster vaccine, neutralizing antibody levels against the original and Delta strains were low but detectable and undetectable for the omicron strain. 
  • Within one week of receiving the booster, neutralizing antibody levels increased 27-fold against the original and Delta strains. By three weeks, this increased up to 243-fold. 
  • Protective neutralizing antibody levels were also rapidly raised against omicron by one-week post-vaccination.
  • Price Action: SNGX shares are up 0.99% at $0.69 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.